{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T06:23:49Z","timestamp":1778826229647,"version":"3.51.4"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.lungcan.2021.12.008","type":"journal-article","created":{"date-parts":[[2021,12,15]],"date-time":"2021-12-15T21:20:30Z","timestamp":1639603230000},"page":"76-83","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Imaging in pleural mesothelioma: A review of the 15th International Conference of the International Mesothelioma Interest Group"],"prefix":"10.1016","volume":"164","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5428-7997","authenticated-orcid":false,"given":"Samuel G.","family":"Armato","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna K.","family":"Nowak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roslyn J.","family":"Francis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sharyn I.","family":"Katz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manizha","family":"Kholmatov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin G.","family":"Blyth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eyjolfur","family":"Gudmundsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew C.","family":"Kidd","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ritu R.","family":"Gill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.lungcan.2021.12.008_b0005","doi-asserted-by":"crossref","unstructured":"Nowak AK, Chansky K, Rice DC, et al. The IASLC Mesothelioma Staging Project: Proposals for Revisions of the T Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Pleural Mesothelioma. J Thorac Oncol 2016;11:2089-99.","DOI":"10.1016\/j.jtho.2016.08.147"},{"key":"10.1016\/j.lungcan.2021.12.008_b0010","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1016\/j.jtho.2016.09.124","article-title":"The IASLC Mesothelioma Staging Project: Proposals for the M descriptors and for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM Classification for Mesothelioma","volume":"11","author":"Rusch","year":"2016","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.lungcan.2021.12.008_b0015","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1016\/j.jtho.2016.09.123","article-title":"The IASLC Mesothelioma Staging Project: Improving staging of a rare disease through international participation","volume":"11","author":"Pass","year":"2016","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.lungcan.2021.12.008_b0020","doi-asserted-by":"crossref","unstructured":"Rice D, Chansky K, Nowak A, et al. The IASLC Mesothelioma Staging Project: Proposals for revisions of the N descriptors in the forthcoming eighth edition of the TNM Classification for Pleural Mesothelioma. J Thorac Oncol 2016;11:2100-11.","DOI":"10.1016\/j.jtho.2016.09.121"},{"issue":"Suppl","key":"10.1016\/j.lungcan.2021.12.008_b0025","doi-asserted-by":"crossref","first-page":"S185","DOI":"10.1016\/j.semcancer.2015.03.004","article-title":"Immune evasion in cancer: Mechanistic basis and therapeutic strategies Review","volume":"35","author":"Vinay","year":"2015","journal-title":"Semin Cancer Biol"},{"key":"10.1016\/j.lungcan.2021.12.008_b0030","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(20)32714-8","article-title":"First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial","author":"Baas","year":"2021","journal-title":"The Lancet"},{"key":"10.1016\/j.lungcan.2021.12.008_b0035","doi-asserted-by":"crossref","unstructured":"Patel SP, Kurzrock R PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy Mol Cancer Ther 2015 Apr;14(4):847-56.","DOI":"10.1158\/1535-7163.MCT-14-0983"},{"issue":"1","key":"10.1016\/j.lungcan.2021.12.008_b0040","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.cpet.2019.08.008","article-title":"Programmed Cell Death-1\/Ligand-1 PET Imaging: A Novel Tool to Optimize Immunotherapy?","volume":"15","author":"Verhoeff","year":"2020","journal-title":"PET Clin"},{"issue":"Suppl 2","key":"10.1016\/j.lungcan.2021.12.008_b0045","first-page":"1","article-title":"Imaging Biomarkers in Immunotherapy","volume":"8","author":"Juergens","year":"2016","journal-title":"Biomark Cancer"},{"key":"10.1016\/j.lungcan.2021.12.008_b0050","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1038\/s41591-018-0255-8","article-title":"89Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer","volume":"24","author":"Bensch","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.lungcan.2021.12.008_b0055","doi-asserted-by":"crossref","first-page":"4664","DOI":"10.1038\/s41467-018-07131-y","article-title":"Whole body PD-1 and PD-L1 positron emission tomography in patients with non-small-cell lung cancer","volume":"9","author":"Niemeijer","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.lungcan.2021.12.008_b0060","doi-asserted-by":"crossref","first-page":"187","DOI":"10.3389\/fonc.2020.00187","article-title":"Immunotherapy in malignant pleural mesothelioma","volume":"10","author":"de Gooijer","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.lungcan.2021.12.008_b0065","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1093\/jnci\/djq310","article-title":"Improved endpoints for cancer immunotherapy trials","volume":"102","author":"Hoos","year":"2010","journal-title":"J Natl Cancer Inst"},{"issue":"7","key":"10.1016\/j.lungcan.2021.12.008_b0070","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1016\/j.jtho.2018.04.010","article-title":"Radiologic pseudoprogression during anti-PD-1 therapy for advanced non-small cell lung cancer","volume":"13","author":"Katz","year":"2018","journal-title":"J Thorac Oncol"},{"issue":"11","key":"10.1016\/j.lungcan.2021.12.008_b0075","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9113483","article-title":"Impact of PET\/CT for assessing response to immunotherapy-A clinical perspective","volume":"9","author":"Lang","year":"2020","journal-title":"J Clin Med"},{"issue":"11","key":"10.1016\/j.lungcan.2021.12.008_b0080","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1200\/JCO.2009.26.3541","article-title":"Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group","volume":"28","author":"Wen","year":"2010","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.lungcan.2021.12.008_b0085","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1158\/2326-6066.CIR-15-0102","article-title":"Radiographic profiling of immune-related adverse events in advanced melanoma patients treated with ipilimumab","volume":"3","author":"Tirumani","year":"2015","journal-title":"Cancer Immunol Res"},{"issue":"3","key":"10.1016\/j.lungcan.2021.12.008_b0090","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.1016\/S1470-2045(17)30074-8","article-title":"RECIST Working Group, iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics","volume":"18","author":"Seymour","year":"2017","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.lungcan.2021.12.008_b0095","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/j.jtho.2018.04.034","article-title":"Revised modified Response Evaluation Criteria in Solid Tumors for assessment of response in malignant pleural mesothelioma (version 1.1)","volume":"13","author":"Armato","year":"2018","journal-title":"J Thorac Oncol"},{"issue":"1","key":"10.1016\/j.lungcan.2021.12.008_b0100","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1158\/0008-5472.CAN-15-1707","article-title":"An effective immuno-PET imaging method to monitor CD8-dependent responses to immunotherapy","volume":"76","author":"Tavare","year":"2016","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.lungcan.2021.12.008_b0105","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/s13550-020-00669-3","article-title":"FDG PET versus CT radiomics to predict outcome in malignant pleural mesothelioma patients","volume":"10","author":"Pavic","year":"2020","journal-title":"EJNMMI Res"},{"key":"10.1016\/j.lungcan.2021.12.008_b0110","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4","article-title":"Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors","volume":"15","author":"Harrell","year":"1996","journal-title":"Stat Med"},{"key":"10.1016\/j.lungcan.2021.12.008_b0115","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1093\/annonc\/mdh059","article-title":"Modified RECIST criteria for assessment of response in malignant pleural mesothelioma","volume":"15","author":"Byrne","year":"2004","journal-title":"Ann Oncol."},{"key":"10.1016\/j.lungcan.2021.12.008_b0120","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1118\/1.3537610","article-title":"Characterization of mesothelioma and tissues present in contrast-enhanced thoracic CT scans","volume":"38","author":"Corson","year":"2011","journal-title":"Med Phys"},{"key":"10.1016\/j.lungcan.2021.12.008_b0125","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1016\/j.jtho.2016.04.027","article-title":"North American multicenter volumetric CT study for clinical staging of malignant pleural mesothelioma: Feasibility and logistics of setting up a quantitative imaging study","volume":"11","author":"Gill","year":"2016","journal-title":"J Thoracic Oncol"},{"key":"10.1016\/j.lungcan.2021.12.008_b0130","doi-asserted-by":"crossref","DOI":"10.1118\/1.4810940","article-title":"Variability of tumor area measurements for response assessment in malignant pleural mesothelioma","volume":"40","author":"Labby","year":"2013","journal-title":"Med Phys"},{"key":"10.1016\/j.lungcan.2021.12.008_b0135","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.lungcan.2020.09.025","article-title":"A comparison between MRI and CT in the assessment of primary tumour volume in mesothelioma","volume":"150","author":"Tsim","year":"2020","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2021.12.008_b0140","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1148\/rg.241035058","article-title":"Malignant pleural mesothelioma: Evaluation with CT, MR imaging, and PET","volume":"24","author":"Wang","year":"2004","journal-title":"Radiographics"},{"key":"10.1016\/j.lungcan.2021.12.008_b0145","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1097\/01.rli.0000131888.39636.c5","article-title":"Asbestos-related pleural disease: Value of dedicated magnetic resonance imaging techniques","volume":"39","author":"Weber","year":"2004","journal-title":"Invest Radiol"},{"key":"10.1016\/j.lungcan.2021.12.008_b0150","doi-asserted-by":"crossref","unstructured":"Tsim S, Alexander L, Kelly C, et al. Serum proteomics and plasma fibulin-3 in differentiation of mesothelioma from asbestos-exposed controls and patients with other pleural diseases. J Thorac Oncol. Published online 2021.","DOI":"10.1016\/j.jtho.2021.05.018"},{"key":"10.1016\/j.lungcan.2021.12.008_b0155","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.lungcan.2018.01.014","article-title":"Early contrast enhancement: A novel magnetic resonance imaging biomarker of pleural malignancy","volume":"118","author":"Tsim","year":"2018","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2021.12.008_b0160","doi-asserted-by":"crossref","unstructured":"Kidd AC, Tsim S, Blyth KG. Technical limitation of semi-automated volumetric analysis using CT in patients with malignant pleural mesothelioma. Pleural Mediastinal Malig. Published online 2019:PA3100.","DOI":"10.1183\/13993003.congress-2019.PA3100"},{"key":"10.1016\/j.lungcan.2021.12.008_b0165","doi-asserted-by":"crossref","first-page":"89","DOI":"10.5858\/arpa.2017-0124-RA","article-title":"Guidelines for Pathologic Diagnosis of Malignant Mesothelioma 2017 Update of the Consensus Statement From the International Mesothelioma Interest Group","volume":"142","author":"Husain","year":"2018","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.lungcan.2021.12.008_b0170","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.ejca.2011.11.036","article-title":"Radiomics: Extracting more information from medical images using advanced feature analysis","volume":"48","author":"Lambin","year":"2012","journal-title":"Eur J Cancer"},{"issue":"2","key":"10.1016\/j.lungcan.2021.12.008_b0175","doi-asserted-by":"crossref","first-page":"W125","DOI":"10.2214\/AJR.09.3519","article-title":"Diffusion-weighted MRI of malignant pleural mesothelioma: preliminary assessment of apparent diffusion coefficient in histologic subtypes","volume":"195","author":"Gill","year":"2010","journal-title":"AJR Am J Roentgenol"},{"issue":"5","key":"10.1016\/j.lungcan.2021.12.008_b0180","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/S1470-2045(10)70218-7","article-title":"Definition and classification of cancer cachexia: an international consensus","volume":"12","author":"Fearon","year":"2011","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.lungcan.2021.12.008_b0185","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1097\/SPC.0000000000000465","article-title":"Cancer cachexia in thoracic malignancy: a narrative review","volume":"13","author":"Kidd","year":"2019","journal-title":"Curr Opin Supportive Palliative Care"},{"issue":"10","key":"10.1016\/j.lungcan.2021.12.008_b0190","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1038\/s41430-019-0418-9","article-title":"Body composition and nutritional status in malignant pleural mesothelioma: implications for activity levels and quality of life","volume":"73","author":"Jeffery","year":"2019","journal-title":"Eur J Clin Nutr"}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016950022100636X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016950022100636X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T12:57:55Z","timestamp":1759237075000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016950022100636X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":38,"alternative-id":["S016950022100636X"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2021.12.008","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Imaging in pleural mesothelioma: A review of the 15th International Conference of the International Mesothelioma Interest Group","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2021.12.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}